A Conversation with Alexandra Johnson, CEO/Co-Founder of Rubber Ducky Labs, AI Recommender Systems Pioneer
The Future of AI Regulation and Legislation: 5 Key Takeaways
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 212: Fujifilm’s Investment in North Carolina with Christine Vannais and Laurie Braxton of Fujifilm
The Privacy Insider Podcast Ep. 8: Privacy Over Party: Peter Swire
Podcast - Robots, Rights and New Tech: Balancing Innovation and Data Privacy
DE Talk | How SMBs Can Use AI Hiring Tech in Inclusive Ways
The Briefing: New California Laws for Digital Replicas Both Live and Dead
Exploring AI's Potential in Financial Services With John Sun of SpringLabs — The Consumer Finance Podcast
Due Diligence in AI: Thinking like your biggest critic
Reel Shorts | Labor & Employment: Navigating AI Compliance Risks in Recruiting
AI Discrimination and Emerging Best Practices – Part 1 — The Good Bot Podcast
Due Diligence in AI: 3 things you need to survive AI scrutiny
How can founders navigate the explosion of state AI regulations?
Using Innovative Technology to Advance Trial Strategies | Episode 70
Dan Rudoy Examines the Impact of AI on IP Strategy
The Burr Broadcast: AI in the Workplace
Exploring the CFPB's Stance on AI in Financial Services — The Consumer Finance Podcast
Joe Green & Monica Rodriguez Kuniyoshi on Integrating Generative AI with Your Experts: Passle CMO Series Live Podcast
Preventative Medicine: Health Care AI Privacy and Cybersecurity – Part 2 — The Good Bot Podcast
When AI Meets PI: Assessing and Governing AI from a Privacy Perspective
The U.S. Food and Drug Administration is all about hard science, and correlation of variables is not evidence of causation. To make a regulatory decision, FDA has long held that line, requiring evidence of actual occurrences...more
Holland & Knight Health Dose is an in-depth weekly dose of legislative and regulatory insights to keep stakeholders abreast of happenings in Washington, D.C., impacting the health sector....more
n March 15, the U.S. Food and Drug Administration (FDA) published a paper titled “Artificial Intelligence and Medical Products: How CBER, CDER, CDRH, and OCP are Working Together.” This paper describes the FDA’s strategy for...more
On March 15, 2024, four of the US Food and Drug Administration’s (FDA) medical products centers released a joint paper, titled “Artificial Intelligence & Medical Products: How CBER, CDER, CDRH, and OCP are Working Together,”...more
The Food and Drug Administration’s (FDA’s) Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER), Center for Devices and Radiological Health (CDRH), and Office of Combination...more
On March 15, 2024, FDA published a white paper titled “Artificial Intelligence & Medical Products: How CBER, CDER, CDRH, and OCP are Working Together” (the AI White Paper) on the use of artificial intelligence (AI) across the...more
On May 10, the U.S. Food and Drug Administration (FDA) published a discussion paper, “Using Artificial Intelligence & Machine Learning in the Development of Drug & Biological Products.” The paper is a collaboration between...more